End Of Century Marks Dawn Of Clinical Trial Era For Cancer Vaccines

The ends of centuries are momentous times for immunology. Edward Jenner introduced the first vaccine, against smallpox, in 1798. New York surgeon William Coley originated immunotherapy in 1893, when he infected cancer patients with killed bacteria to stimulate immunity against their tumors. And now, in the 1990s, "cancer vaccines" are finally in widespread clinical trials. Cancer vaccines are making headlines and have been the focus of five international scientific conferences in the past two y

Written byRicki Lewis
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

The ends of centuries are momentous times for immunology. Edward Jenner introduced the first vaccine, against smallpox, in 1798. New York surgeon William Coley originated immunotherapy in 1893, when he infected cancer patients with killed bacteria to stimulate immunity against their tumors. And now, in the 1990s, "cancer vaccines" are finally in widespread clinical trials.

Cancer vaccines are making headlines and have been the focus of five international scientific conferences in the past two years. "At least 50 institutions have research groups working on tumor vaccines," says Lynn Spitler, president of Jenner Technologies Inc., a private company based in Danville, Calif. Spitler was chairwoman of the second international conference on Engineered Vaccines for Cancer and AIDS, held in San Francisco March 3 to 5.

SHOOTING FOR BEST RESULTS: Lynn Spitler notes that at least 50 institutions are working on cancer vaccines. Among them are her firm, Jenner Technologies Inc. and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Accelerating Recombinase Reprogramming with Machine Learning

Accelerating Recombinase Reprogramming with Machine Learning

Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

DNA and pills, conceptual illustration of the relationship between genetics and therapeutic development

Multiplexing PCR Technologies for Biopharmaceutical Research

Thermo Fisher Logo

Products

waters-logo

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

zymo-research-logo

Zymo Research Partners with Harvard University to Bring the BioFestival to Cambridge, Empowering World-class Research

10x-genomics-logo

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA